The YpsoMate 1.0 will gradually replace the current available metoject/metex pen for the German company’s methotrexate products. Ypsomed launched its new autoinjector in various countries during the first quarter of this year.
Medac develops subcutaneous methotrexate (MTX) products, introducing the first pre-filled MTX autoinjector in Europe 10 years ago. The medication — delivered on a weekly basis — treats various autoimmune diseases including rheumatoid arthritis, psoriasis, and Crohn’s disease.
Ypsomed says its new autoinjector offers several advantages, including a simple, two-step initiation for the injection process. The user removes the protective cap and presses the device against the skin, automatically triggering the injection. This device requires no button press to administer therapy.
The YpsoMate pen also delivers audible signals that indicate the start and end of the injection, providing added confidence to patients. Its injection needle is concealed both before and after injection by a safety mechanism as well. This protects against needle-stick injuries and ensures that users don’t see the needle. The autoinjector also has a square shape, offering an easy-to-grip option prevented from rolling on flat surfaces.
Ypsomed says it developed its YpsoMate platforms for the simple and safe handling of various medications and volumes. It designed the pens so even those with impaired grip and vision can administer their medication easily and safetly on their own.
